Goldman Sachs throws in $37M with Chinese replacement heart valve maker Venus Medtech
The Venus P-valve pulmonary replacement has already been implanted in more than 40 patients, and the current goal is to win CE Mark approval. They will reportedly be enrolling patients to accomplish this in the early half of the year.